Grace Therapeutics (GRCE) vs. The Competition Financial Review

Grace Therapeutics (NASDAQ:GRCE) is one of 1,072 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare Grace Therapeutics to similar companies based on the strength of its earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability and risk.

Insider and Institutional Ownership

6.1% of Grace Therapeutics shares are held by institutional investors. Comparatively, 44.0% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 13.5% of Grace Therapeutics shares are held by insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Grace Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Grace Therapeutics	N/A	-20.10%	-17.10%
Grace Therapeutics Competitors	-3,399.87%	-235.11%	-32.77%

Earnings & Valuation

This table compares Grace Therapeutics and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Grace Therapeutics	N/A	-$12.85 million	-1.99
Grace Therapeutics Competitors	$9.93 billion	$136.87 million	-7.35

Grace Therapeutics’ rivals have higher revenue and earnings than Grace Therapeutics. Grace Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Grace Therapeutics and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grace Therapeutics	0	0	1	0	3.00
Grace Therapeutics Competitors	8376	22218	50369	1347	2.54

Grace Therapeutics presently has a consensus price target of $12.00, indicating a potential upside of 419.48%. As a group, “Pharmaceutical preparations” companies have a potential upside of 216.30%. Given Grace Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Grace Therapeutics is more favorable than its rivals.

Volatility and Risk

Grace Therapeutics has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Grace Therapeutics’ rivals have a beta of 3.64, meaning that their average share price is 264% more volatile than the S&P 500.

Summary

Grace Therapeutics beats its rivals on 7 of the 13 factors compared.

About Grace Therapeutics

Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.